Fig. 4From: AXL in cancer: a modulator of drug resistance and therapeutic targetAXL-mediated epithelial–mesenchymal transition (EMT) in drug-resistant cancer. AXL is known to activate EMT transcription factors through three pathways to promote EMT transformation and drug resistance of cancer cells. These pathways include AKT/GSK-3β/β-catenin, TGF-β/Smad3, and PI3K/AKT/HIF-1αBack to article page